...structural studies to guide compound optimization. TARGET/MARKER/PATHWAY: S. aureus monofunctional glycosyltransferase LICENSING STATUS: Patented by Alchemia Ltd....
...Zuegg, J. et al. Nat. Commun.; published online July 21, 2015 doi:10.1038/ncomms8719 CONTACT: Wim Meutermans, Alchemia Ltd....

...Panther will acquire Alchemia’s Alchemia Oncology Pty Ltd. subsidiary in a deal slated to close by...
...a Phase II trial as second-line treatment of mCRC. The companies could not be reached. Alchemia Ltd....

...of OS showed that both treatment arms led to an OS of about 14 months. Alchemia...
...and said it will report further on its review and corporate strategy in early 2015. Alchemia...
...Bristol-Myers Squibb Co. (NYSE:BMY, New York, N.Y.) and Merck KGaA (Xetra:MRK, Darmstadt, Germany) market Erbitux. Alchemia Ltd....

...Novartis AG’s Australia and New Zealand group; he succeeds Jenni Pilcher, who became CFO of Alchemia Ltd. WIR...

...Ltd. (ASX:IMU), Armadale, Australia Business: Drug delivery Hired: Charles Walker as CEO, formerly CEO of Alchemia Ltd. WIR...

...Inc. (TSX: AEZ; NASDAQ:AEZS) Macimorelin acetate (AEZS-130) Diagnose adult growth hormone deficiency PDUFA date 11/5/14 Alchemia Ltd....

...in about 50 patients with mCRC. HA-Irinotecan is in Phase III testing to treat mCRC. Alchemia...
...Merck markets the drug elsewhere, except in Japan where the 3 companies market the drug. Alchemia Ltd....

...of PFS, which resulted in fewer events by June 30 than the company originally planned. Alchemia...
...statistical power of the FDA-requested substudy (see BioCentury, Feb. 11, 2013 & March 4, 2013). Alchemia...